Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Operating Overview Life Science Investing
Larimar Therapeutics Announces Proposed $75 Million Underwritten Public Offering Life Science Investing
Maravai Lifesciences Reports Fourth Quarter and Full Year 2025 Financial Results Life Science Investing
Codexis to Report Fourth Quarter and Fiscal Year 2025 Financial Results on March 11 Life Science Investing
Tempest Announces Interim Results from Ongoing REDEEM-1 Trial of TPST-2003, Preparing for Potential U.S. Registrational Study in 2026 Life Science Investing
Anavex Life Sciences to Present at the 46th TD Cowen Annual Health Care Conference Life Science Investing
